Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 15/20 | 0.41 |
| ▸ | PAK1 | Q13153 | 3/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21485550 | 0.81 | CD38 (0.47) | CRHR1CRHR2 | |
| SCHEMBL21506248 | 0.80 | PAK1 (0.43) | PAK1 | |
| SCHEMBL21481785 | 0.78 | PAK1 (0.45) | CRHR1PAK1 | |
| SCHEMBL21506732 | 0.76 | CRHR1 (0.40) | CRHR1CRHR2 | |
| SCHEMBL24991869 | 0.75 | PKM (0.38) | MEN1ALDH1A1KMT2A | |
| SCHEMBL22927154 | 0.74 | JAK1 (0.44) | CRHR1MEN1ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL21506745 | 0.71 | TNF (0.38) | PAK1KMT2A | |
| SCHEMBL228958 | 0.70 | DRD2 (0.52) | MEN1KMT2A | |
| SCHEMBL224991 | 0.70 | DRD2 (0.52) | MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL224992 | 0.69 | DRD2 (0.51) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190315712-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315712-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | CRHR1 87/4885PAK1 1555/4885CRHR2 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.